Developing a new treatment for non-small cell lung cancer using a targeted antibody
Antitumor potential of AvFc lectibody in non-small cell lung cancer
This study is exploring a new treatment for non-small cell lung cancer that uses a special molecule to help the immune system better fight the cancer, and it's currently being tested in animals to see how safe and effective it is before moving on to people.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10717195 on NIH RePORTER |
What this research studies
This research focuses on creating a novel treatment for non-small cell lung cancer (NSCLC) by targeting specific markers on cancer cells. The approach involves using a specially designed molecule called Avaren-Fc (AvFc), which can recognize and bind to high-mannose glycans found on the surface of malignant cells. By enhancing the immune response against these cancer cells, the treatment aims to improve the effectiveness of existing therapies, especially in advanced stages of the disease. The research includes testing the safety and effectiveness of AvFc in various animal models to gather data before potential human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced non-small cell lung cancer who have not responded well to current therapies.
Not a fit: Patients with early-stage non-small cell lung cancer or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with advanced non-small cell lung cancer.
How similar studies have performed: Other research has shown promise in using targeted immunotherapy approaches for cancer treatment, indicating potential success for this novel method.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Matoba, Nobuyuki — University of Louisville
- Study coordinator: Matoba, Nobuyuki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.